Fundraising Fox

Vivace Therapeutics

San Mateo, US · Founded 2014 · Delaware corporation · 4 known investors

vivacetherapeutics.com ↗

Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.

BiotechHealthtechMedical Devices

Founders & leadership

Vivace Therapeutics was founded in 2014 by Shuang Qiao.

SQ
Shuang QiaoFounder
SD
Sheng DingNamed on SEC filing

Board

EH
Edward HuBoard director
JWJun Wu
Jun WuBoard directorChairman and Managing Partner at Cenova Capital
JSJake Simson
Jake SimsoninBoard directorPartner at RA Capital
TSTim Shannon
Tim Shannonin𝕏Board directorGeneral Partner at Canaan Partners
CZ
Chenguang ZhouBoard director

Investors · 4

Canaan Partners✓ verifiedStamford · $500K – $20Mvia Tim Shannon · board
RA Capital✓ verifiedBoston
Cenova CapitalShanghai
Mission BiocapitalSan Francisco · $500K

Funding

SEC filings, press & company announcements

$60.5M disclosed across 4 of 5 rounds · 2015–2026

▶$17.5MraisedMar 2025 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward HuDirector
  • Jun WuDirector
  • Jake SimsonDirector
  • Tim ShannonDirector
  • Chenguang ZhouDirector
  • Shuang QiaoExecutive Officer, Director
Offering amount
$35M
Amount sold
$17.5M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedDec 2020 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shuang QiaoExecutive Officer, Director
  • Edward HuDirector
  • Leonard PostDirector
  • Tim ShannonDirector
  • Jun WuDirector
  • Chenguang ZhouDirector
Offering amount
$30M
Amount sold
$30M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedMay 2018 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Leonard PostExecutive Officer, Director
  • Shuang QiaoExecutive Officer, Director
  • Edward HuDirector
  • Tim ShannonDirector
  • Jun WuDirector
Offering amount
$25M
Amount sold
$8M
First sale
May 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJan 2015 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Shuang QiaoExecutive Officer, Director
  • Edward HuDirector
  • Tim ShannonDirector
  • Sheng DingExecutive Officer
Offering amount
$15.1M
Amount sold
$5M
First sale
Jan 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Bioworld32 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Vivace Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Funding Roundup: Recent Financing Rounds Completed for Pain, Cancer, and Musculoskeletal Care Innovations | PharmExecpharmexec.com · Jul 2026Vivace Therapeutics Secures $35M in Series D to Advance Cancer Drug VT3989technews180.com · Mar 2025Vivace Therapeutics raises $35 million to push mesothelioma drug toward late-stage trial - San Francisco Business Timesbizjournals.com · Mar 2025Vivace Therapeutics Raises $35 Million in Series D Financing to Support Clinical Development of First-in-Class Cancer Drug Targeting the Hippo Pathwayprnewswire.com · Mar 2025Vivace Therapeutics Raises $40M in Series A and Series B Funding - FinSMEsfinsmes.com · Jun 2017

Frequently asked questions

What does Vivace Therapeutics do?
Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
Who founded Vivace Therapeutics?
Vivace Therapeutics was founded by Shuang Qiao in 2014.
Who are Vivace Therapeutics's investors?
Vivace Therapeutics's investors include Canaan Partners, RA Capital, Cenova Capital, Mission Biocapital.
How much funding has Vivace Therapeutics raised?
Vivace Therapeutics has disclosed $60.5M raised across 4 of its 5 known rounds.
Where is Vivace Therapeutics headquartered?
Vivace Therapeutics is headquartered in San Mateo, US.